CELL GENESYS CANCER DRUG GETS FAST-TRACK STATUS
The FDA has granted fast-track status to Cell Genesys' GVAX immunotherapy for prostate cancer.
GVAX, the company's lead product candidate for the treatment of advanced prostate cancer, is being studied in two Phase III clinical trials expected to involve about 1,200 patients. The first trial will compare GVAX to Taxotere chemotherapy plus prednisone. The second trial will compare GVAX plus Taxotere chemotherapy to Taxotere plus prednisone.